Drug Development

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Articles

Topical drugs are attractive to patients, but these complex products pose challenges for formulators.

Balancing the Art and Science of Topical Drug Formulation

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Accelerated formulation strategies are a useful tool to reduce development timelines and cost, but key priorities must be considered early on to ensure success.

Focusing on Accelerated Formulation Strategies

Aaron Stewart is associate principal scientist at Lonza Pharma and Biotech, Bend, OR.

In-vitro and in-silico tools can help predict in-vivo outcomes for low-solubility drugs formulated as spray-dried dispersions. 

Advancing Spray-Dried Dispersion Formulation Development

A Phase III trial evaluating the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, in adolescents 12 to 15 years of age showed 100% efficacy and positive antibody responses. 

Pfizer-BioNTech COVID-19 Vaccine Shows Positive Results in Clinical Trial for Adolescents

Set to be operational in 2026, the new facility will provide added antigen and filling capacity for Sanofi’s influenza vaccine, increasing its availability in Canada, the United States, and Europe.

Sanofi to Invest More than $700 million into New Canadian Vaccine Manufacturing Facility

GSK will provide filling capacity at its Barnard Castle facility in England.

GSK to Support Manufacture of Novavax' COVID-19 Vaccine Candidate

Celonic will manufacture CvnCoV at its facility in Germany.

Celonic Group to Manufacture CureVac’s mRNA COVID Vaccine Candidate

The company has entered into an agreement with the African Vaccine Acquisition Trust for the supply of 220 million doses of its single-shot COVID-19 vaccine for the African Union’s 55 member states beginning in the third quarter of 2021. 

J&J to Supply the African Union with 200 Million Doses of its COVID-19 Vaccine

EMA has approved the manufacturing of drug product for BioNTech’s COVID-19 vaccine, BNT162b2, at BioNTech’s manufacturing site located in Marburg, Germany. 

EMA Approves BioNTech’s COVID-19 Vaccine Manufacturing Site

AstraZeneca has released the results of its primary analysis of the Phase III trial data evaluating its COVID-19 vaccine.

Formulation and Drug Delivery